Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus exemestane in postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer after prior NSAI therapy
2011-006111-62Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus and exemestane in breast cancer, sponsored by Novartis. Primary endpoint: Overall response rate. Started Mar 2012; status: completed.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-006111-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006111-62.